John Xu

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

Tracy T. Batchelor, Paul Mulholland, Bart Neyns et al. · Journal of Clinical Oncology · 2013 · 598 citations · Full text

Medicine, Oncology, Pharmacology +17

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

Paresh Dandona, Chantal Mathieu, Moshe Phillip et al. · The Lancet Diabetes & Endocrinology · 2017 · 292 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study

Paresh Dandona, Chantal Mathieu, Moshe Phillip et al. · Diabetes Care · 2018 · 238 citations

Medicine, Pharmacology, Pharmacotherapy +17

Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function

S. Petrykiv, C. David Sjöström, Peter J. Greasley et al. · Clinical Journal of the American Society of Nephrology · 2017 · 152 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials

Per‐Henrik Groop, Paresh Dandona, Moshe Phillip et al. · The Lancet Diabetes & Endocrinology · 2020 · 78 citations

Medicine, Endocrinology, Pharmacology +6